WO2002078684A3 - Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders - Google Patents

Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders Download PDF

Info

Publication number
WO2002078684A3
WO2002078684A3 PCT/US2002/010115 US0210115W WO02078684A3 WO 2002078684 A3 WO2002078684 A3 WO 2002078684A3 US 0210115 W US0210115 W US 0210115W WO 02078684 A3 WO02078684 A3 WO 02078684A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
treatment
carbon monoxide
inhibiting
vascular
Prior art date
Application number
PCT/US2002/010115
Other languages
French (fr)
Other versions
WO2002078684A2 (en
Inventor
Roland Buelow
Jacky Woo
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Priority to IL15818202A priority Critical patent/IL158182A0/en
Priority to EP02757910A priority patent/EP1381354A2/en
Priority to CA002442457A priority patent/CA2442457A1/en
Priority to MXPA03008820A priority patent/MXPA03008820A/en
Priority to JP2002576950A priority patent/JP2004526739A/en
Publication of WO2002078684A2 publication Critical patent/WO2002078684A2/en
Publication of WO2002078684A3 publication Critical patent/WO2002078684A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods and compositions are provided for treating vascular disease and modulating the inflammatory and immune processes using carbon monoxide generating compounds, including methylene chloride. The subject compounds are capable of inhibiting the proliferation of vascular smooth muscle cells, protecting the vasculature against oxidative stress and injury, modulating the activity of various immune system cells, inhibiting the production of pro-inflammatory cytokines and enhancing production of anti-inflammatory cytokines, thereby being effective in the treatment of conditions associated with adverse proliferative or inflammatory responses. Methods for extending the survival of an organ transplant and inhibiting chronic rejection in a recipient are also provided.
PCT/US2002/010115 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders WO2002078684A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL15818202A IL158182A0 (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vacular, inflammatory and immune disorders
EP02757910A EP1381354A2 (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
CA002442457A CA2442457A1 (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
MXPA03008820A MXPA03008820A (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders.
JP2002576950A JP2004526739A (en) 2001-03-30 2002-04-01 Carbon monoxide producing compounds for the treatment of vascular, inflammatory and immune disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28052601P 2001-03-30 2001-03-30
US60/280,526 2001-03-30

Publications (2)

Publication Number Publication Date
WO2002078684A2 WO2002078684A2 (en) 2002-10-10
WO2002078684A3 true WO2002078684A3 (en) 2002-12-19

Family

ID=23073455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010115 WO2002078684A2 (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Country Status (9)

Country Link
US (1) US20030068387A1 (en)
EP (1) EP1381354A2 (en)
JP (1) JP2004526739A (en)
CN (1) CN1507348A (en)
CA (1) CA2442457A1 (en)
IL (1) IL158182A0 (en)
MX (1) MXPA03008820A (en)
RU (1) RU2003131675A (en)
WO (1) WO2002078684A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
SK15942003A3 (en) * 2001-06-21 2004-08-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants apoptosis
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2005525848A (en) * 2002-02-13 2005-09-02 ベス イスラエル ディコネス メディカル センター Treatment method of vascular disease
AU2003216368B2 (en) * 2002-04-15 2007-08-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
AU2003223562B2 (en) * 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
JP2005532314A (en) * 2002-05-09 2005-10-27 イエール ユニバーシティ Carbon monoxide as a biomarker and therapeutic agent
US20040052866A1 (en) 2002-05-17 2004-03-18 Otterbein Leo E. Methods of treating hepatitis
CA2487413A1 (en) * 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP5020525B2 (en) * 2006-03-30 2012-09-05 財団法人生産開発科学研究所 Ligand substitution infusion formulation
US20100196516A1 (en) * 2007-04-24 2010-08-05 ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda Treatment of infections by carbon monoxide
US8778413B2 (en) * 2010-05-14 2014-07-15 Ikaria, Inc. Dosing regimens and methods of treatment using carbon monoxide
ES2628634T3 (en) 2011-07-21 2017-08-03 Alfama, Inc. Carbon monoxide-ruthenium releasing molecules and uses thereof
WO2013022946A1 (en) 2011-08-09 2013-02-14 Beth Israel Deaconess Medical Center, Inc. Methods of treating dna damage
CN105288599A (en) * 2015-10-22 2016-02-03 徐州医学院 Application of heme oxygenase-2 in preparing preparations inhibiting organ transplantation immune rejection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHINESE MEDICAL SCIENCES JOURNAL, vol. 14, no. 1, 1999, pages 41 - 45 *
CRITICAL CARE MEDICINE, vol. 27, no. 11, November 1999 (1999-11-01), pages 2435 - 2441 *
CYTOKINE, vol. 11, no. 5, May 1999 (1999-05-01), pages 326 - 333 *
DATABASE HCAPLUS [online] OU ET AL.: "Role of endogenous carbon monoxide in neointimal formation induced by balloon-injury in rat aorta", XP002957476, Database accession no. 1999:248211 *
DATABASE MEDLINE [online] DINGLEY ET AL.: "Blood volume determination by the carbon monoxide method using a new delivery system: accuracy in critically ill humans and precision in an animal model", XP002957474, accession no. STN Database accession no. 2000043862 *
DATABASE MEDLINE [online] TAMION ET AL.: "Induction of haem oxygenase contributes to the synthesis of pro-inflammatory cytokines in re-oxygenated rat macrophages: role of cGMP", XP002957475, accession no. STN Database accession no. 199262228 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Also Published As

Publication number Publication date
US20030068387A1 (en) 2003-04-10
CN1507348A (en) 2004-06-23
CA2442457A1 (en) 2002-10-10
WO2002078684A2 (en) 2002-10-10
IL158182A0 (en) 2004-03-28
EP1381354A2 (en) 2004-01-21
MXPA03008820A (en) 2004-07-30
JP2004526739A (en) 2004-09-02
RU2003131675A (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2002078684A3 (en) Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
IS2822B (en) Inhibits human phosphatidyl-inositol 3-kinase delta
EP1648385A4 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2004064716A3 (en) Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
DK0786991T3 (en) Polyamine Compounds for the Treatment of Proliferative Vascular Diseases
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2006055871A3 (en) Treatment for multiple sclerosis
EP1635815A4 (en) Methods and compounds for the treatment of vascular stenosis
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2005118592A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
PL1891961T3 (en) Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
CA2430467A1 (en) Means and method for treating an intimal dissection after stent implantation
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2000000634A3 (en) METHODS OF INHIBITING $i(HELICOBACTER PYLORI)
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: PA/a/2003/008820

Ref document number: 2442457

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002576950

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 158182

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002307022

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002757910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 028094328

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002757910

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002757910

Country of ref document: EP